Arecor Therapeutics plc (AIM:AREC)
London · Delayed Price · Currency is GBP · Price in GBX 71.50
0.00 (0.00%)
Oct 29, 2025, 3:53 PM GMT+1
Arecor Therapeutics Revenue
Arecor Therapeutics had revenue of 2.00M GBP in the half year ending June 30, 2025, with 20.01% growth. This brings the company's revenue in the last twelve months to 5.06M, up 3.31% year-over-year. In the year 2024, Arecor Therapeutics had annual revenue of 5.05M with 10.50% growth.
Revenue (ttm)
5.06M
Revenue Growth
+3.31%
P/S Ratio
5.33
Revenue / Employee
115.02K
Employees
44
Market Cap
27.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.05M | 480.00K | 10.50% |
| Dec 31, 2023 | 4.57M | 2.17M | 90.30% |
| Dec 31, 2022 | 2.40M | 1.25M | 107.51% |
| Dec 31, 2021 | 1.16M | -540.00K | -31.80% |
| Dec 31, 2020 | 1.70M | -192.99K | -10.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 31.63B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Arecor Therapeutics News
- 4 weeks ago - Half Year 2025 Arecor Therapeutics PLC Earnings Presentation Transcript - GuruFocus
- 4 weeks ago - AIM Market Roundup: Wishbone, Nativo Resources, Arecor Therapeutics - The Armchair Trader
- 4 weeks ago - LGND: Ligand Pharmaceuticals Inks $11M Royalty Deal with Arecor - GuruFocus
- 4 weeks ago - Arecor extends cash runway with US partnerships - The Armchair Trader
- 4 months ago - Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing - Seeking Alpha
- 5 months ago - AIM Market Roundup: The Revel Collective, Tanfield, Arecor - The Armchair Trader
- 6 months ago - Full Year 2024 Arecor Therapeutics PLC Earnings Presentation (Shareholder Q&A) Transcript - GuruFocus
- 1 year ago - Half Year 2024 Arecor Therapeutics PLC Earnings Presentation Transcript - GuruFocus